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Abstract
Introduction Patients initiated on highly active antiretro-
viral therapy (HAART) generally remain on medication
indefinitely. A modification in the HAART regimen may
become necessary because of possible acute or chronic
toxicities, concomitant clinical conditions, development of
virological failure or the advent of adverse drug events.
The study documents adverse drug events of HIV-positive
Ghanaian patients with HAART modifications. It also
investigates the association between documented adverse
drug events and HAART modification using an unmatched
case–control study design.
Method The study was conducted in the Fevers Unit of the
Korle Bu Teaching Hospital and involved patients who
attended the HIV Care Clinic between January 2004 and
December 2009. Data from 298 modified therapy patients
(cases) were compared with 298 continuing therapy
patients (controls) who had been on treatment for at least
1 month before the end of study. Controls were sampled
from the same database of a cohort of HIV-positive
patients on HAART, at the time a case occurred, in terms
of treatment initiation ±1 month. Data were obtained from
patients’ clinical folders and the HIV clinic database linked
to the pharmacy database. The nature of the documented
adverse drug events of the cases was described and the
association between the documented adverse drug events
and HAART modification was determined by logistic
regression with reported odds ratios (ORs) and their 95 %
confidence interval (CI).
Results Among the 298 modified therapy patients sampled
in this study, 52.7 % of them had at least one documented
adverse drug event. The most documented adverse drug
event was anaemia, recorded in 18.5 % of modified therapy
patients, all of whom were on a zidovudine-based regimen.
The presence of documented adverse drug events was
significantly associated with HAART modification [ad-
justed OR = 2.71 (95 % CI 2.11–3.48), p\ 0.001].
Conclusion Among HIV patients on HAART, adverse
drug events play a major role in treatment modification.
Occurrence of adverse drug events may be used as a pre-
dictor for possible therapy modification. We recommend
the institution of active pharmacovigilance in HIV treat-
ment programmes as it permits the proper identification
and characterisation of drug-related adverse events. This
can help develop approaches towards their management
and also justify therapy modifications.
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Key Points
Adverse drug events lead to highly active
antiretroviral therapy (HAART) regimen
modification.
Active pharmacovigilance systems should be
emphasised to identify and characterise drug-related
adverse events in HAART-treatment patients.
1 Introduction
Patients started on highly active antiretroviral therapy
(HAART) generally remain on medication indefinitely.
The World Health Organization (WHO) recommends first-
line regimens involving two nucleoside reverse transcrip-
tase inhibitors (NRTIs) and one non-nucleoside reverse
transcriptase inhibitor (NNRTI) antiretroviral (ARV) drug
[1, 2]. Second-line regimens are started when the first-line
regimens are ineffective. The provision of second-line
regimens in resource-limited settings is generally a chal-
lenge [3, 4].
Therapy modifications in ARV regimens become nec-
essary because of possible acute or chronic toxicities,
concomitant clinical conditions, development of virologi-
cal failure or the advent of adverse drug events. Drug
substitution is defined as the replacement of one or more
drugs in the first-line ARV regimen (NRTI or NNRTI) with
another drug from the same ARV class (NRTI or NNRTI),
e.g. the substitution of nevirapine (NVP) with efavirenz
(EFV) or the substitution of an NRTI, stavudine (d4T),
with zidovudine (ZDV). Therapy switch on the other hand
refers to the change from the first-line NRTI-based
HAART to a second-line protease inhibitor-based ARV
regimen [1, 5].
A major constraint of HAART is the high prevalence of
adverse drug events among patients receiving HAART.
Adverse drug events are a very common complication of
ARV therapy and a major reason for patients defaulting
during HIV therapy [6]. The incidence is high in the initial
stages, but tends to decrease later, though long-term events
such as lipodystrophy may occur [7, 8]. Up to 25 % of
patients discontinue their initial HAART regimen because
of treatment failure, toxic effects or non-adherence within
the first 12 months of therapy [6, 9]. This poses a huge
challenge in the fight against HIV. While research for less
toxic ARVs continue, it is important to monitor treatment-
associated toxicities with a view to understanding and
managing them where possible.
The approach to patients who need HAART modifica-
tion depends on several factors. These include the reason
for change, previous HAART experience, available treat-
ment options and the tolerability of the HAART. In addi-
tion, adverse drug events associated with some ARVs (e.g.
lipodystrophy, anaemia, renal impairment) further limit the
type of ARVs that can be administered to patients [10, 11].
Adverse drug events, if not managed effectively, will lead
to medication non-adherence and invariably to treatment
failure [10, 11].
In Ghana, the Korle Bu Teaching Hospital (KBTH) has
been providing HAART services to patients living with
HIV/AIDs (PLWHA) since 2003 at a token fee of US $3.00
in response to the WHO ‘‘3 by 5’’ initiative for all nations,
with the objective of placing 3 million persons living with
HIV on HAART by 2005 [12]. As at 2015, about 11,000
people living with HIV/AIDS were on HAART in the
KBTH, with some on treatment for the past 11 years. No
singular effort has been made to analyse the factors asso-
ciated with HAART modification from the data generated
so far. There is also limited local data on the profile of
adverse drug events. Determining the various factors
associated with HAART modification and profiling the
adverse drug events in patients on ARVs is an important
step to the success of any HAART programme.
The study was in two parts; the first part describes all
adverse drug events documented at most 12 months prior
to therapy modification in HIV-positive patients who
modified HAART at the KBTH in Accra, Ghana, and the
second part determines the association between the pres-
ence of adverse drug events as a primary exposure and
HAART modification as the outcome.
2 Methods
2.1 Setting
This study was conducted in the Fevers Unit of the KBTH,
the premier teaching hospital in Ghana. As of December
2009, about 4850 patients have been initiated on HAART,
with about 3440 of them still on treatment. There are three
major outpatient clinic days per week, each with an aver-
age attendance of 120 patients. As at the time of study, the
total number of therapy modifications was about 400 cases.
Patients included in the study attended the HIV Care Clinic
between January 2004 and December 2009. The HIV clinic
runs an electronic database, which served as the source of
data. The first-line HAART guidelines in place during the
study period were either d4T ? lamivudine (3TC) ? NVP
or d4T ? 3TC ? EFV or ZDV ? 3TC ? NVP or ZDV?
3TC ? EFV, i.e. d4T/3TC/NVP or d4T/3TC/EFV or ZDV/
3TC/NVP or ZDV/3TC/EFV. HAART classification as
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first line or second line was based on the recommendations
of the ‘‘Guidelines for Antiretroviral Therapy in Ghana’’
[5]. Regimens in this study are either d4T-based regimens
or ZDV-based regimens depending on the type of NRTI
involved.
2.2 Study Design and Patient Population
This is an unmatched case–control study using data docu-
mented in patients’ clinical folders during previous hospital
visits. The study used data from 298 modified therapy
patients (cases) and 298 continuing therapy patients (con-
trols) who had been on HAART between January 2004 and
December 2009 and had been on treatment at least 1 month
before the end of study. Only patients 15 years or older
who were enrolled at the Fevers Unit of the KBTH, were
on triple therapy and had available clinical and pharmacy
records were included in the study. Cases were defined as
patients aged 15 years or older who were on modified
HAART (modified therapy patients). Changes in dose were
not considered as modified therapy. Controls were defined
as patients aged 15 years or older who were still on their
initiating HAART (continuing therapy patients). Controls
were sampled from the same database of a cohort of HIV-
positive patients on HAART at the time a case occurred in
terms of treatment initiation ±1 month. Given that cases
and controls were sampled based on treatment initiation
date, every risk pair had a similar period of observation.
A sample size of 298 each for cases and controls was
determined as described by Strom [13], with the following
assumptions: 10 % expected prevalence of adverse drug
events in the controls, a minimum odds ratio (OR) of 2.0 to
be detected, a type I error of 5 %, a type II error of 20 %
(power of 80 %) and a ratio of cases to controls of 1:1.
2.3 Data Collection and Definitions
The outcome variable in this study was HAART modifi-
cation (i.e. patients who modified initiating ARV therapy
compared with patients who continued with initiating
ARV), whilst the primary exposure of interest was docu-
mented adverse drug events at most 12 months prior to end
of study. Data were obtained from patients’ clinical folders
and the HIV clinic database linked to the pharmacy data-
base. We extracted documented adverse drug events from
the clinical folders of patients as recorded by the attending
physician during patients’ follow-up post-treatment initia-
tion. The clinical folder was designed by the National
AIDS Control Programme (NACP) [5] for the Ghana
Health Service in accordance with recommendations from
the WHO, and has specific adverse drug event sections to
be completed by the attending specialist physician on each
patient’s clinic visit. All trained HIV care physicians at all
HIV care centres nationwide use this specifically designed
clinical folder for every HIV-positive patient on each clinic
visit. A sub-section of this clinical folder lists the following
adverse drug events for the attending physician to look out
for or examine on each clinic visit of the patient; anaemia,
rash, diarrhoea ([3 days), pancreatitis, hepatotoxicity,
pain/numbness/tingling in extremities, blood in urine,
lipodystrophy and depression in addition to other adverse
drug event(s) noticed [5]. For the purposes of this study, all
adverse drug events documented in the clinical folder at
most 12 months prior to HAART modification or end of
study were used in assessing the presence of adverse drug
events. No causality assessment was done on the adverse
drug events data retrieved from documented records. We
collected data on socio-demographic, clinical, immuno-
logical and virological parameters of the study participants,
including gender, education at baseline, marital status at
baseline, source of funding health care and occupation at
baseline. Clinical and immunological baseline data col-
lected prior to initiation of HAART included presence of
systemic signs and symptoms, CD4 count, WHO staging
and type of HAART regimen administered. All data
extraction from the clinical folders and the electronic
database was done by a trained specialist clinical phar-
macist, the lead author, using a standardised template that
was piloted prior to study implementation to maintain
uniformity.
2.4 Data Analysis
Data were double entered, cleaned and managed using
Microsoft Access (Microsoft Corporation, Redmond,
Washington, USA) and analysed using Stata 11.0 (Col-
lege Station, Texas, USA). Data were expressed as fre-
quencies and percentages for categorical variables.
Documented adverse drug event data were reviewed and
coded using Medical Dictionary for Regulatory Activities
(MedDRA) (Version 13.1) terminology and grouped by
System Organ Class (SOC) Preferred Term (PT) according
to therapy type. MedDRA is a clinically validated inter-
national medical terminology used by regulatory authori-
ties, and it organises adverse events by SOC divided into
high level group terms (HLGTs), high level terms (HLTs),
PTs and lowest level terms (LLTs).
Continuous variables were reported as mean ± standard
deviation or median with interquartile (IQR) range if not
normally distributed. The presence of documented adverse
drug events was the primary exposure variable, whilst
HAART modification is the outcome variable. Predictors
of HAART modification were determined by logistic
regression and reported as OR with corresponding 95 %
confidence interval (CI). Covariates for the multivariate
analysis were selected by the change-in-estimate method
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such that variables that change the crude estimate of the
association between documented adverse drug events and
HAART modification by more than 10 % were considered
confounders [14, 15]. All statistical tests were two-sided,
and p\ 0.05 was considered statistically significant.
3 Results
3.1 Study Population
During the study period between January 2004 and
December 2009, 400 patients had their HAART modified.
The total number of participants in this study was 596.
Cases and controls were similar in socio-demographic
characteristics: median age 43.0 years (IQR 36–51) in
cases versus 43.0 years (IQR 36–52) in controls and a
female population of 65.4 % (n = 195) in cases versus
64.4 % (n = 192) in controls (Table 1).
Clinical characteristics of cases and controls are shown
in Table 2. The median duration from initiation of therapy
to end of study was 344.5 days (IQR 101.5–882.5) for the
cases and 374 days (IQR 104.5–898.3) for the controls. At
least one adverse drug event was documented in 157
(52.7 %, 95 % CI 46.8–58.5) of the cases and 12 (4.0 %,
95 % CI 2.1–6.9) of the controls.
3.2 Description of Documented Adverse Drug
Events
A review of the clinical folders of the cases indicated that
157 modified therapy patients (52.7 %) had at least one
documented adverse drug event, 13 patients (4.4 %) had
two documented adverse drug events and 144 patients
(95.6 %) had one documented adverse drug event
(Table 3). From Table 3, the most documented adverse
drug event was anaemia (SOC red blood cell disorder),
reported in 18.5 % (n = 55) of the modified therapy
Table 1 Socio-demographic
baseline characteristics of case
and control subjects
Characteristics Case subjects [n (%)]a Control subjects [n (%)]a
Age at HAART initiation N = 298 N = 298
Median (interquartile range), years 43 (36–51) 43 (36–52)
Gender N = 298 N = 298
Female 195 (65.4) 192 (64.4)
Male 103 (34.6) 106 (35.6)
Marital status N = 293 N = 296
Single 63 (21.5) 55 (18.6)
Married/cohabiting 159 (54.3) 160 (54.0)
Divorced/separated/widowed 71 (24.2) 81 (27.4)
Educational status N = 288 N = 295
None 42 (14.6) 41 (13.9)
Primary/junior high school 132 (45.8) 137 (46.4)
Senior high school 87 (30.2) 92 (31.2)
Tertiary 27 (9.4) 25 (8.5)
Employment status N = 284 N = 294
Unemployed 32 (11.3) 27 (9.2)
Employed 252 (88.7) 267 (90.8)
Smoking N = 293 N = 295
Non-smoker 273 (93.2) 278 (94.2)
Smoker 20 (6.8) 17 (5.8)
Alcohol use N = 293 N = 295
Non-drinker 239 (81.6) 241 (81.7)
Drinker 54 (18.4) 54 (18.3)
Source of funding N = 289 N = 293
Self 180 (62.3) 203 (69.3)
National health insurance and other sources 109 (37.7) 90 (30.7)
HAART highly active antiretroviral therapy
a Data are reported as n (%) unless otherwise stated
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patients. Metabolic and nutritional disorders were docu-
mented in 12.4 % (n = 37) of the modified therapy
patients, whilst peripheral neuropathy was documented in
8.7 % (n = 26) of the modified therapy patients (Table 3).
3.3 Association Between Documented Adverse Drug
Events and HAART Modification
The presence of documented adverse drug events was
significantly associated with HAART [crude OR = 2.27
(95 % CI 1.89–2.72)] in the univariate analysis (Table 4).
Other factors associated with HAART modification in the
univariate analysis were WHO HIV staging at HAART
initiation, body mass index (BMI) at HAART initiation,
presence of systemic signs and symptoms at HAART ini-
tiation and CD4 count at HAART initiation. However,
when the change-in-estimate method was used to deter-
mine potential confounders to the association between
documented adverse drug events and HAART modifica-
tion, only BMI at HAART initiation changed the crude OR
by[10 % and was thus included in the multivariate anal-
ysis. After adjusting for this possible confounder, the odds
of HAART modification was 2.71 in patients with docu-
mented adverse drug events [adjusted OR = 2.71 (95 % CI
2.11–3.48), p\ 0.001].
Sub-group analysis of the outcome variable indicated
significant association between documented adverse drug
events and first-line to first-line HAART modification
[adjusted OR = 2.88 (95 % CI 2.22–3.74), p\ 0.001], but
no association with first-line to second-line HAART
modification [adjusted OR = 2.33 (95 % CI 0.69–7.91),
p = 0.175].
4 Discussion
4.1 Profile of Documented Adverse Drug Events
At least one adverse drug event was documented in 52.7 %
(n = 157) of modified therapy patients, as against 4 %
(n = 12) of continuing therapy patients. Similar to other
findings, anaemia, nutritional and metabolic disorders and
peripheral neuropathy were the most documented adverse
drug events [11, 16]. The most documented adverse drug
Table 2 Clinical characteristics of case and control subjects
Characteristics Case subjects [n (%)]a Control subjects [n (%)]a
Duration from HAART initiation to end of study N = 298 N = 298
Median (interquartile range), days 344.5 (101.5–882.5) 374 (104.5–898.3)
Documented adverse event N = 298 N = 298
Present 157 (52.7) 12 (4.0)
Absent 141 (47.3) 286 (96.0)
WHO HIV stage at HAART initiation N = 293 N = 296
Stage I–III 229 (78.2) 251 (84.8)
Stage IV 64 (21.8) 45 (15.2)
BMI at HAART initiation N = 240 N = 240
Underweight (\18.00 kg/m2) 76 (31.7) 51 (21.3)
Normal weight/overweight/obese (C18.00 kg/m2) 164 (68.3) 189 (78.7)
Presence of systemic signs and symptoms at HAART initiation N = 294 N = 298
Yes 163 (55.4) 128 (43.0)
No 131 (44.6) 170 (57.0)
CD4 T lymphocytes count at HAART initiation N = 293 N = 295
\150 cells/mm3 203 (69.3) 168 (56.9)
C150 cells/mm3 90 (30.7) 127 (43.1)
HAART regimen administered N = 298 N = 298
ZDV/3TC/EFV 70 (23.5) 85 (28.5)
ZDV/3TC/NVP 71 (23.8) 76 (25.5)
d4T/3TC/EFV 84 (28.2) 63 (21.1)
d4T/3TC/NVP 60 (20.1) 61 (20.5)
Others 13 (4.4) 13 (4.4)
3TC lamivudine, BMI body mass index, d4T stavudine, EFV efavirenz, HAART highly active antiretroviral therapy, NVP nevirapine, WHO
World Health Organization, ZDV zidovudine
a Data are reported as n (%) unless otherwise stated
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event among the entire study population was anaemia
(19.6 %, n = 58), mostly from the use of ZDV, but which
was totally absent in patients on d4T-based therapy. A
cohort study at the same study site cited anaemia as the
most documented adverse drug event [11], similar to other
studies [16]. Metabolic disturbances and peripheral neu-
ropathy, the next most documented adverse drug events,
were documented mostly in the d4T-based therapies, but
were totally absent in the ZDV-based therapies. Red blood
cell disorders, metabolic and nutritional disorders and
peripheral neuropathy were the three leading documented
events. Among this group, practically all the people who
had a documented red blood cell disorder had been given a
ZDV combination. ZDV has long been known to cause
anaemia, because of its myelosuppressive activity [17–20].
This haematological reaction occurs when ZDV is given in
dosages of C1500 mg daily. Lower dosages of ZDV are
used in triple combination therapy as first-line to reduce
this reaction. Use of other medications that inhibit cyto-
chrome P450 may also enhance the side effects of ZDV
since they can inhibit its hepatic metabolism [17, 21, 22].
Patients who experienced metabolic and nutritional disor-
ders had been given a d4T combination. The majority of
people who experienced peripheral neuropathy were also
on d4T, and they reported a greater variety of adverse drug
events. These adverse drug events with d4T have been
demonstrated in several studies [23–25]. Metabolic and
nutritional disorders such as hyperlactataemia, lactic aci-
dosis, lipoatrophy and in some cases hypertriglyceridaemia
as well as hypercholesterolaemia [26] can lead to several
cardiovascular diseases. Ter Hofsted et al. noted that these
effects are also more pronounced with higher doses of d4T
and recommend plasma monitoring of d4T as a way to
prevent d4T-associated lipoatrophy [25].
Studies have shown that the most common adverse
effects associated with discontinuation of HAART are
gastrointestinal [6]. These commonly include anorexia,
nausea, vomiting and diarrhoea. A pharmacovigilance
study of adults on HAART in South Africa indicated that
out of a total of 2585 patients monitored over a period of
Table 4 Socio-demographic and clinical factors associated with HAART modification
Characteristic Crude odds ratio
[95 % CI]
P value Adjusted odds ratio
[95 % CI]a
P value
Age at HAART initiation 1.00 [0.99–1.02] 0.884 – –
Gender Male 0.96 [0.68–1.34] 0.797 – –
Female 1.00
Smoking status Smoker 1.20 [0.62–2.34] 0.596 – –
Non-smoker 1.00
Alcohol use Drinker 1.01 [0.66–1.53] 0.969 – –
Non-drinker 1.00
Documented adverse drug event Present 2.27 [1.89–2.72] \0.001 2.71 [2.11–3.48] \0.001
Absent 1.00 1.00
WHO HIV staging at HAART
initiation
IV 1.56 [1.02–2.37] 0.039 – –
I–III 1.00




Systemic signs and symptoms at
HAART initiation
Present 1.65 [1.19–2.29] 0.002 – –
Absent 1.00
CD4 T lymphocytes count at HAART
initiation
\150 cells/mm3 1.71 [1.22–2.39] 0.002 – –
C150 cells/mm3 1.00
HAART regimen administered ZDV/3TC/NVP 1.13 [0.72–1.78] 0.585 – –
d4T/3TC/EFV 1.62 [1.03–2.55] 0.038 – –
d4T/3TC/NVP 1.19 [0.74–1.92] 0.465 – –
Others 1.21 [0.53–2.79] 0.647 – –
ZDV/3TC/EFV 1.00
3TC lamivudine, BMI body mass index, CI confidence interval, d4T stavudine, EFV efavirenz, HAART highly active antiretroviral therapy, NVP
nevirapine, WHO World Health Organization, ZDV zidovudine
a Only variables that changed the association between documented adverse drug event and HAART modification by more than 10 % were
included in the multivariate analysis as cofounders
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5 years, 34.5 % had their initiation regimens changed and
this substitution/switch occurred on average of
14.9 months after HAART initiation [27]. The study also
showed that the four most common adverse drug events
experienced by the patients who switched therapy due to
ARV-related toxicity were polyneuropathy (24.0 %),
lipodystrophy (23.9 %), neuropathy (10.6 %) and sus-
pected lactic acidosis (3.8 %). Another study in a South
African cohort indicated that the frequency of therapy
switch (within 3 years of HAART initiation) due to NVP
toxicity is about 8 %, EFV toxicity 2 % and ZDV toxicity
8 % [28]. The study also indicated that therapy switch due
to d4T toxicity occurred in 21 % of patients due to
symptomatic hyperlactataemia (5 %), lipodystrophy (9 %)
or peripheral neuropathy (6 %).
The high proportion of first-line to first-line HAART
modification (80.5 %, n = 240) versus first-line to second-
line HAART modification (19.5 %, n = 58) among the
modified therapy patients participating in this study is
similar to that reported in other studies in developed
countries [29, 30]. The median duration of 344.5 days from
HAART initiation to HAART modification is comparable
with a southern Indian study on generic HAART modifi-
cation of 406 days [31] and a South African study of
14.9 months (447 days) [27]. This indicates that patients
fared generally well on the initiating regimen for at least
a year before modification of therapy. The modifications
could therefore be due to persistent adverse drug events,
policy changes or treatment failures.
4.2 Association Between Documented Adverse Drug
Events and HAART Modification
The presence of documented adverse drug events was
significantly associated with HAART modification [ad-
justed OR = 2.71 (95 % CI 2.11–3.48), p\ 0.001]. This is
in conformation with results from other studies that also
indicated that the experience of adverse drug events is a
very common reason for HAART modification in HIV-
positive patients on HAART therapy [6, 32–38]. Clearly,
the issue of the relationship between occurrence of adverse
drug events and HAART modification is an extremely
important one that deserves further concerted study across
several countries and with a larger number of patients,
especially considering the fact that HIV has now become a
chronic condition, with patients likely to be on life-long
therapy. In addition, the proportion of patients experienc-
ing an adverse drug event before therapy modification in
this study is similar to the proportions found in studies by
Padua et al. in Brazil [35] and Tadesse et al. in Ethiopia
[37], which indicated that 56.1 and 53.8 %, respectively, of
patients who modified to another therapy self-reported at
least one adverse drug reaction [35, 37]. A similar case–
control study in Ethiopia, however, showed that as high as
85.7 % of patients on HAART had changed therapy [32].
4.3 Clinical and Policy Implications
Adverse drug events associated with HAART have become
a major public health concern, especially in relation to poor
adherence to complex regimens in PLWHA [39]. Poor
adherence to HAART due to experienced adverse drug
events may even be prevalent regardless of the relationship
of these events to HAART. It is therefore important to have
an active pharmacovigilance programme in all HIV treat-
ment programmes that permits the proper identification and
characterisation of drug-related adverse events and to also
develop approaches towards their management.
The presence of drug toxicity and/or poor medication
adherence may limit any derived benefit from HAART and
often results in therapy modifications which can be costly.
HAART modification in resource-constrained settings like
Ghana is costly as it narrows down on the regimen options
available to patients, thereby posing a major challenge to
the effectiveness of the ongoing treatment. This also poses
challenges to the national programme, especially in the
limited choice of regimens available to patients in this
setting. In addition, although HAART modification could
itself be an option for the management of adverse drug
events, it can also lead to the development of new and
severe adverse drug events, further complicating any future
regimen options available.
In resource-limited settings, HIV clinics should closely
monitor adverse drug events with both clinical and labo-
ratory investigations in order to provide early interventions
to mitigate any untoward HAART modification [31]. Most
adverse drug events are determined clinically by the use of
specific signs and symptoms, including fatigue with con-
junctival pallor (due to ZDV-related anaemia), neuropsy-
chiatric problems (due to EFV), peripheral wasting (due to
d4T-related lipodystrophy) and rash (due to NVP, EFV or
abacavir) [40]. At the KBTH, patients undergo regular
medical review, laboratory examinations, adherence
counselling and general education on the disease and its
management in order to overcome noncore HAART
modifications. Adherence is reviewed at every clinic visit
and documented, and is considered satisfactory when
patients’ self-report of compliance tallies with pill count. In
addition, it will be important to establish standardised
protocols for adverse drug event monitoring to improve the
recognition, management and prevention of these events
[41]. Management of adverse drug events including dose
adjustment and the choice of appropriate regimen is a key
strategy for improving adherence among HIV-positive
patients on therapy and the avoidance of any subsequent
therapy modification [42].
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Tenofovir as an alternative to ZDV in potentially
anaemic patients (baseline haemoglobin of 8–10 g/dL) is
now the preferred first-option regimen choice in response
to the toxic effects of ZDV. The finding that low CD4
counts (\150 cells/mm3) at HAART initiation was asso-
ciated with HAART modification in this study supports the
current modified WHO recommendations that HAART
should be started in patients with even high CD4 counts of
500 cells/mm3 [43]. Adherence to this new WHO recom-
mendation will ensure that patients initiated on HAART
have lower odds of HAART modification and also the
development of adverse drug events in the early stages of
treatment. The current findings carry some clinical impli-
cations, which should be carefully considered in future
studies, especially in African subjects who are prone to
haemoglobinopathies and are more likely to develop
adverse drug events with ZDV use [44]. The limited ARV
regimen options may therefore present potential challenges
to clinicians with time in resource-limited settings.
4.4 Limitations
A limitation of this study is that the findings cannot be
generalised across all HIV treatment sites in Ghana since
the study was localised to the KBTH. However, the liter-
ature review presents similarities with other studies done in
Africa and beyond, thus rendering the study results
worthwhile for any policy review. Self-reporting of adverse
drug events by patients may have served as a limitation
since the culture of spontaneous reporting of adverse drug
events is absent in the African population and health pro-
fessionals have to prompt reporting from most patients.
Initial adherence counselling of patients should emphasise
the reporting of all adverse drug events. Poor record-
keeping practices also served as a limitation in retrieving
complete data sets on patients; therefore, the use of elec-
tronic data capture should be encouraged.
This study is further limited by the lack of routine
baseline viral load determination, which could have served
to confirm treatment failure in some patients and therefore
the need for therapy switch. This could have served also as
a predictor of therapy switch since patients with very high
viral load tend to have low CD4 count and often present
with relatively more severe opportunistic infections. Owing
to resource challenges, random primary HAART resistance
testing is not carried out at baseline or in a failing regimen;
therefore, we were unable to determine what possible effect
primary resistance to the ARVs in use might have had on
our findings. Again no duplicate data extraction was done
as it required another clinical pharmacist to be engaged
specifically for that aspect of work, but efforts were made
to ensure extracted data from the clinical folders matched
with data from the electronic database.
4.5 Conclusion
These findings indicate that among HIV-positive patients
on HAART, adverse drug events play a major role in
treatment modifications (substitution or switch). Occur-
rence of adverse drug events may be used as a predictor for
possible therapy modification. The institution of active
pharmacovigilance in HIV treatment programmes permits
the proper identification and characterisation of drug-re-
lated adverse events and can help to develop approaches
towards their management and justified therapy modifica-
tion. Monitoring adverse drug events and managing them
appropriately may help to avoid dispensable therapy
modifications.
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